Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
6.00
-0.15 (-2.44%)
Jul 23, 2026, 12:24 PM EDT - Market open
Entrada Therapeutics Market Cap
Entrada Therapeutics has a market cap or net worth of $216.2 million as of July 23, 2026. Its market cap has decreased by -3.88% in one year.
Market Cap
216.20M
Enterprise Value
11.45M
1-Year Change
-3.88%
Ranking
Category
Stock Price
$6.00
ChartMarket Cap Chart
Since the IPO on October 29, 2021, Entrada Therapeutics's market cap has decreased from $251.01M to $216.20M, a decrease of -13.87%. That is a compound annual growth rate of -3.10%.
| Date | Market Cap | % Change |
|---|---|---|
| Jul 23, 2026 | 216.20M | -41.35% |
| Dec 31, 2025 | 368.66M | -39.78% |
| Dec 31, 2024 | 612.16M | 21.70% |
| Dec 29, 2023 | 503.01M | 18.72% |
| Dec 30, 2022 | 423.70M | -20.71% |
| Dec 31, 2021 | 534.36M | 112.88% |
| Oct 29, 2021 | 251.01M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Fulcrum Therapeutics | 241.21M |
| Cartesian Therapeutics | 240.34M |
| Adagene | 239.18M |
| Conexeu Sciences | 237.61M |
| Protara Therapeutics | 228.75M |
| Anavex Life Sciences | 224.27M |
| AC Immune | 223.20M |
| Orchestra BioMed Holdings | 222.16M |